MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-04-2025
Corcept Therapeutics Incorporated Total Liabilities 2011-2026 | CORT
Annual Total Liabilities Corcept Therapeutics Incorporated
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 161 M | 115 M | 81.6 M | 48 M | 48.4 M | 41.1 M | 35.8 M | 29.6 M | 27.4 M | 33.4 M | 38 M | 42.1 M | 37.4 M | 5.03 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 161 M | 5.03 M | 53.1 M |
Quarterly Total Liabilities Corcept Therapeutics Incorporated
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 192 M | 166 M | 163 M | 145 M | 118 M | 108 M | 132 M | 103 M | 88.3 M | - | 59.9 M | - | 60.3 M | 48 M | 45.2 M | 45.8 M | 41.6 M | 48.4 M | 48.4 M | 48.4 M | 48.4 M | 41.1 M | 41.1 M | 41.1 M | 41.1 M | 35.8 M | 35.8 M | 35.8 M | 35.8 M | 29.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 192 M | 29.6 M | 73.1 M |
Total Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
1.98 B | - | 2.43 % | $ 254 M |  Germany |
 |
ARCA biopharma
ABIO
|
13.8 M | - | 1052.0 % | $ 415 M |  USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
337 M | $ 18.38 | -0.68 % | $ 2.7 B | USA |
 |
Amgen
AMGN
|
50 B | $ 344.65 | 0.81 % | $ 185 B | USA |
 |
Arrowhead Pharmaceuticals
ARWR
|
106 M | $ 71.99 | 3.84 % | $ 9.63 B | USA |
 |
Biogen
BIIB
|
11.3 B | $ 178.18 | -0.95 % | $ 25.9 B | USA |
 |
I-Mab
IMAB
|
707 M | - | - | $ 866 M |  China |
 |
Aytu BioScience
AYTU
|
93.3 M | $ 2.65 | 1.92 % | $ 16.6 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.45 B | - | - | $ 40.3 B | USA |
 |
Adagene
ADAG
|
38.7 M | $ 2.96 | 7.64 % | $ 167 M | China |
 |
Biophytis SA
BPTS
|
20.4 M | - | -13.47 % | $ 169 M |  France |
 |
Burford Capital Limited
BUR
|
1.45 B | $ 9.83 | 1.44 % | $ 1.59 B |  Britain |
 |
Midatech Pharma plc
MTP
|
6.46 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Can-Fite BioPharma Ltd.
CANF
|
3.45 M | $ 4.16 | 3.74 % | $ 9.05 B |  Israel |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.16 M | - | -1.52 % | $ 24.7 M | USA |
 |
Akero Therapeutics
AKRO
|
75.8 M | - | - | $ 3.67 B | USA |
 |
Alterity Therapeutics Limited
ATHE
|
5.89 M | $ 3.18 | 0.32 % | $ 7.65 B |  Australia |
 |
Acorda Therapeutics
ACOR
|
395 M | - | -24.86 % | $ 820 K | USA |
 |
Compugen Ltd.
CGEN
|
18.5 M | $ 1.86 | 1.1 % | $ 167 M | Israel |
 |
Aptose Biosciences
APTO
|
14.7 M | - | -45.71 % | $ 1.2 M |  Canada |
 |
Acasti Pharma
ACST
|
5.38 M | - | 4.01 % | $ 150 M | Canada |
 |
Celldex Therapeutics
CLDX
|
45.3 M | $ 24.86 | 1.06 % | $ 1.6 M | USA |
 |
Cellectis S.A.
CLLS
|
253 M | $ 3.87 | 2.22 % | $ 116 M | France |
 |
Aeglea BioTherapeutics
AGLE
|
90.7 M | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
272 M | $ 1.41 | - | $ 264 M | USA |
 |
Albireo Pharma
ALBO
|
126 M | - | -0.23 % | $ 916 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.1 B | - | - | - |  Russia |
 |
Allena Pharmaceuticals
ALNA
|
15.9 M | - | 3.16 % | $ 1.9 M | USA |
 |
Ascendis Pharma A/S
ASND
|
1.29 B | $ 224.87 | -0.54 % | $ 5 B |  Danmark |
 |
Ampio Pharmaceuticals
AMPE
|
2.38 M | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
46.6 M | - | - | $ 10.1 M | USA |
 |
Aravive
ARAV
|
51.5 M | - | -13.39 % | $ 1.45 M | USA |
 |
BioNTech SE
BNTX
|
3.12 B | $ 110.01 | -3.29 % | $ 27.2 B | Germany |
 |
Athira Pharma
ATHA
|
13.9 M | - | - | $ 269 M | USA |
 |
Aeterna Zentaris
AEZS
|
21.9 M | - | 5.93 % | $ 314 M | Canada |
 |
Autolus Therapeutics plc
AUTL
|
355 M | $ 1.39 | 1.5 % | $ 355 M | Britain |
 |
AgeX Therapeutics
AGE
|
6.61 M | - | -10.17 % | $ 12.2 K | USA |
 |
AVROBIO
AVRO
|
6.35 M | - | 1083.1 % | $ 745 M | USA |
 |
Cardiff Oncology
CRDF
|
14.2 M | $ 1.73 | -1.43 % | $ 82.4 M | USA |
 |
Akouos
AKUS
|
45.1 M | - | 0.23 % | $ 488 M | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
243 M | - | -15.15 % | $ 60.3 M | Britain |
 |
DBV Technologies S.A.
DBVT
|
38.3 M | $ 21.75 | 0.65 % | $ 2.11 B | France |
 |
Brickell Biotech
BBI
|
6.5 M | - | -5.38 % | $ 6.06 M | USA |
 |
Amneal Pharmaceuticals
AMRX
|
3.32 B | $ 14.25 | 4.13 % | $ 4.4 B | USA |
 |
AIkido Pharma
AIKI
|
7.27 M | - | 1.93 % | $ 17.4 M | USA |
 |
Atreca
BCEL
|
76.6 M | - | -11.76 % | $ 5.79 M | USA |
 |
CureVac N.V.
CVAC
|
470 M | - | - | $ 867 M | Germany |
 |
Acer Therapeutics
ACER
|
28.4 M | - | 2.71 % | $ 14 M | USA |
 |
BioCryst Pharmaceuticals
BCRX
|
966 M | $ 6.72 | 2.05 % | $ 1.39 B | USA |